1月5日主力资金净流出557.22万元；游资资金净流入428.34万元；散户资金净流入128.88万元。 公司公告汇总 截至2026年1月5日收盘，迈得医疗(688310)报收于15.94元，上涨3.98%，换手率2.72%，成交量4.53万 手，成交额7176.69万元。 当日关注点 交易信息汇总 资金流向 迈得医疗工业设备股份有限公司关于以集中竞价交易方式首次回购公司股份的公告 迈得医疗工业设备股份有限公司于2026年1月5日通过集中竞价交易方式首次回购公司股份127,283股， 占公司总股本的0.0766%。回购价格区间为15.69元/股至15.80元/股，支付资金总额2,004,504.07元（不含 交易费用）。本次回购系基于公司2025年12月30日经股东会审议通过的回购方案，回购资金来源为超募 资金或自有资金，拟用于减少注册资本，回购期限为12个月，回购金额区间为2,000万元至4,000万元， 回购价格上限为24元/股。本次回购符合相关法规及公司方案规定。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 迈得医疗工业设 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 一、回购股份的基本情况 迈得医疗工业设备股份有限公司（以下简称"公司"）于2025年12月11日、2025年12月30日分别召开第五 届董事会第八次会议、2025年第二次临时股东会，审议通过了《关于以集中竞价交易方式回购公司股份 方案的议案》，同意公司以首次公开发行股票超募资金或自有资金通过集中竞价交易方式回购公司已发 行的部分人民币普通股（A股）股票，用于减少公司注册资本，回购金额不低于人民币2,000万元 （含），不超过人民币4,000万元（含），回购价格不超过24元/股（含），回购期限为自股东会审议通 过本次回购股份方案之日起12个月内。具体内容详见公司于2025年12月31日披露在上海证券交易所网站 （www.sse.com.cn）的《迈得医疗工业设备股份有限公司关于以集中竞价交易方式回购股份的回购报告 书》（公告编号：2025-057）。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一一回购股份》等相 ...

Suspension and Resumption - ChuanYin High-Tech: The stock is suspended as the offer period for the acquisition by China Seed Group has expired [1] Private Placement - Weigao Blood Purification: Plans to issue shares to acquire 100% equity of Weigao Purui at a transaction price of 8.511 billion yuan [2] - Haopeng Technology: Plans to raise no more than 800 million yuan through a private placement for energy storage battery construction projects and steel shell stacked lithium battery projects [2] Equity Transfer and Increase - Tengya Precision: The controlling shareholder intends to transfer 5.7% of shares at a price of 14.47 yuan per share [3] - JinFang Energy: Yang Jianxun and his concerted parties plan to transfer a total of 10.46% of shares [4] - Hengyi Petrochemical: The controlling shareholder and concerted parties adjusted the share buyback price range from no more than 10 yuan per share to no more than 15 yuan per share [4] Daily Operations and External Investments - Fulian Precision: A subsidiary plans to invest a total of 8.7 billion yuan to build a project with an annual production capacity of 500,000 tons of high-end lithium iron phosphate for energy storage [5] - Defu Technology: A wholly-owned subsidiary signed a cooperation intention agreement with a well-known domestic CCL enterprise to supply high-end electronic circuit copper foil products [5] - Tianchen Medical: Signed a strategic cooperation agreement with Inspur Digital Technology (Shanghai) to jointly invest in R&D resources for medical robots [5] - Xusheng Group: Recently received a notification from a North American electric vehicle manufacturer for supplying components, with a project lifecycle of about 8 years and a total sales amount of approximately 7.8 billion yuan [5] - Jinguang Equipment: Plans to invest about 581 million yuan in the construction of the third phase of the complete equipment industrialization project for filtration [7] - Guizhou Tire: Plans to invest 299 million USD in Morocco to build an intelligent manufacturing project for semi-steel radial tires [9] - Zhejiang Mining: Plans to acquire 100% equity of Alaigyr Company, which owns lead-silver mines in Kazakhstan [10] - Feiwo Technology: Recently completed the acquisition of 60% equity in liquid rocket engine component company Xinsai Aerospace [11] - Tianci Materials: Plans to suspend production for maintenance on the 150,000-ton liquid lithium hexafluorophosphate production line at the Longshan North base [12] Performance Changes - Chifeng Gold: Expects a net profit of 3 billion to 3.2 billion yuan in 2025, an increase of approximately 70% to 81% year-on-year [13] - Dingtai High-Tech: Expects a net profit of 410 million to 460 million yuan in 2025, a year-on-year growth of 81% to 103% [13] - China National Materials: Expects a net profit of 1.55 billion to 1.95 billion yuan in 2025, a year-on-year increase of 73.79% to 118.64% [13] - Ugreen Technology: Expects a net profit of 653 million to 733 million yuan in 2025, a year-on-year growth of 41.26% to 58.56% [13] - Huayou Cobalt: Expects a net profit of 5.85 billion to 6.45 billion yuan in 2025, a year-on-year increase of 40.80% to 55.24% [13]

2025年12月19日至21日，首届进博优品交易会（以下简称"小进博"）在国家会展中心（上海）举行。作为进博会在会期 外的延伸，本次活动聚焦优质消费产品，是"共享大市场·出口中国"系列中的重要一环。 在现场，3H馆和4.1H馆内人流如织，汇集60多个国家和地区的700多家企业，打造了一场为期三天的"年末消费嘉年华"。 众多进博会同款新品从展台直达消费现场，让普通观众一站式选购"进博年货"，切实感受开放共赢的市场活力。 首发新品引领消费新浪潮 如果说惠民折扣点燃了消费热情，那么馆内的"进博首发新品汇"则展现了"首发经济"的蓬勃活力。 展台上的巧克力、饼干等多款进口食品前都围满了试吃的市民，不少人一买就是好几袋。"第一天就卖了几百箱，加起来 有七八千袋。"工作人员语气里满是惊喜。 在巴西圣保罗投促局展台，来自南美大陆的风味同样吸引众多观众。"我们的速溶咖啡选用巴西山多士优质咖啡豆，口感 柔和不苦涩。"工作人员手持产品向围观市民演示冲泡方法，"平时68元一盒，现在买3盒送2盒，折算下来一杯黑咖才一 块多钱。"市民王女士听完立刻下单5盒："家里人都爱喝咖啡，这个价格比代购还划算，正好囤着当年货。" 美妆服饰区域更是优 ...

摘要 ： 作为流式细胞样本前处理设备，CytoNexus实现了全封闭操作、自动化流程和即插即用设计等多项创新性突破。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 2025 年 12 月 下旬，江苏卓微生物科技有限公司正式推出流式细胞样本前处理革新性产品 —Cy toNexus 全封闭・全自动・即用型智能系 统。该产品凭借全封闭操作、自动化流程、即插即用设计三大核心突破，直击行业痛点，为临床检验、科研实验、生物制药等领域带来标准 化、高效化的样本前处理解决方案，引发行业关注。 ▉ 直击行业痛点，填补市场空白 当前流式细胞分析的样本前处理环节长期面临多重困境：人工操作需 30-60 分钟 / 样本，批量处理压力大，人力 成本高；手工操作差异导 致 CV 值常超 15%，数据可比性差；开放操作易产生气溶胶，存在交叉污染与职业暴露风险。即便现有自动化设备，也存在价格昂贵、操作 复杂、纯化效率低、样本适应性局限等问题。 Cy toNexus 的推出精准解决了这些痛点，其以 "全封闭、全自动、即用型" 为核心定位，专为流式细胞分析设计，可自动完成裂 ...

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., has shown a notable increase in stock performance and is involved in the medical imaging and industrial non-destructive testing equipment sectors, benefiting from the pet economy and the depreciation of the RMB [1][2][3]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and went public on January 22, 2025. The company specializes in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing devices [7]. - The company's main business revenue composition includes: medical ultrasound (71.16%), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and others (1.26%) [7]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 254 million yuan, representing a year-on-year decrease of 2.90%. The net profit attributable to the parent company was approximately 88.94 million yuan, down by 3.66% year-on-year [7][8]. - As of September 30, 2025, the company had a total market capitalization of 9.667 billion yuan [1]. Market Activity - On January 5, 2025, the company's stock price increased by 4.78%, with a trading volume of approximately 79.35 million yuan and a turnover rate of 6.08% [1]. - The company has seen a net outflow of 1.42 million yuan from major investors, indicating a lack of strong control by major shareholders, with a very dispersed distribution of shares [4][5]. Industry Context - The company is positioned within the medical device sector, specifically under the categories of medical imaging and non-destructive testing, which are part of the broader healthcare and technology industries [7]. - The company benefits from trends in the pet economy and advancements in medical technology, as evidenced by its participation in industry events such as the 97th WVC Annual Conference [2].

Group 1 - The pharmaceutical and biotechnology industry is entering a critical phase of innovation realization and global layout, with a resonance of industrial, policy, and capital cycles expected by 2026, leading to a potential performance inflection point and valuation reshaping for Chinese innovative drugs, particularly in next-generation therapies such as ADCs, bispecific/multispecific antibodies, cell and gene therapies, and small nucleic acids [1] - The impact of policies on the medical device industry is diminishing, with over half of the market covered by centralized procurement, allowing domestic companies to achieve technological breakthroughs in certain high-end fields and surpass foreign competitors, alongside rapid growth in exports, which are expected to increase by 7.3% year-on-year from January to November 2025 [1] - The medical equipment sector is driven by a significant increase in procurement volume, with a projected 40% year-on-year growth in bidding amounts for 2025, positioning flow-type products and high-end export enterprises for high growth [1] - The demand for blood products and plasma collection continues to grow, with resources concentrating towards leading companies, and stable demand for major products such as albumin and immunoglobulin [1] Group 2 - The ChiNext Medical ETF (159377) tracks the Innovative Medicine Index (399275), which has a daily price fluctuation limit of 20%, and selects listed companies in the biotechnology, genetic engineering, and new drug development sectors from the ChiNext market to reflect the overall performance of high-growth and innovative biopharmaceutical frontier enterprises [1]

Group 1 - The core viewpoint of the news is that Jianxin Superconductor's stock price has shown a slight increase of 2.04% this year, but has experienced a significant decline of 19.34% over the past five trading days [2] - As of January 5, the stock price is reported at 43.00 yuan per share, with a total market capitalization of 7.21 billion yuan [1] - The company has seen a net outflow of main funds amounting to 5.70 million yuan, with large orders showing a buy of 8.60 million yuan and a sell of 11.41 million yuan [1] Group 2 - Jianxin Superconductor, established on December 11, 2013, specializes in the research, production, and sales of core components for medical magnetic resonance imaging (MRI) equipment [2] - The company's revenue composition includes superconducting products at 69.14%, permanent magnet products at 25.35%, and other supplementary products at 5.51% [2] - For the period from January to September 2025, Jianxin Superconductor achieved a revenue of 393 million yuan, reflecting a year-on-year growth of 37.34%, and a net profit attributable to shareholders of 47.62 million yuan, with a year-on-year increase of 38.54% [2]

每经AI快讯，1月5日，沪指高开0.46%，深成指高开0.80%，创业板指高开0.84%，人脑工程、贵金属、 石油石化等板块指数涨幅居前。脑机接口概念表现活跃，创新医疗涨停，美好医疗、三博脑科20cm涨 停，倍益康、爱朋医疗、翔宇医疗涨超10%，博拓生物、伟思医疗跟涨。 （文章来源：每日经济新闻） ...

Group 1 - The core viewpoint of the news is that 港通医疗 (Kangtong Medical) has shown a mixed performance in terms of financing and stockholder metrics, with a notable decrease in revenue and profit in recent periods [1][2]. Group 2 - As of December 31, 港通医疗's stock price increased by 0.30%, with a trading volume of 18.21 million yuan [1]. - The financing data indicates that on the same day, 港通医疗 had a financing buy amount of 1.00 million yuan and a financing repayment of 1.77 million yuan, resulting in a net financing buy of -0.77 million yuan [1]. - The total financing and margin trading balance for 港通医疗 reached 28.46 million yuan, which is 2.03% of its circulating market value, indicating a low financing balance compared to the past year [1]. Group 3 - 港通医疗's main business involves providing medical institutions with overall solutions centered on medical gas systems and clean operating rooms, with revenue contributions of 55.69% from clean equipment and systems, 37.30% from medical gas equipment and systems, and 4.06% from other medical equipment sales [1]. - As of December 19, the number of shareholders for 港通医疗 increased to 7,539, while the average circulating shares per person decreased to 8,362 shares [2]. - For the period from January to September 2025, 港通医疗 reported a revenue of 344 million yuan, a year-on-year decrease of 30.06%, and a net profit attributable to the parent company of -10.21 million yuan, a year-on-year decrease of 150.92% [2]. Group 4 - 港通医疗 has distributed a total of 48.99 million yuan in dividends since its A-share listing [3]. - As of September 30, 2025, the top ten circulating shareholders included 诺安多策略混合A (Noah Multi-Strategy Mixed A), which holds 725,100 shares as a new shareholder [3].